Related Experiment Video
Updated: Jan 14, 2026

Author Spotlight: Comparing Alveolar and Long Bone Remodeling to Explore OTM Model Potential
Published on: July 21, 2023
Sclerostin antibody promotes alveolar bone regeneration after tooth extraction
Erdal Ergünol1, Rabia Şemsi2, Duygu Dayanır3
1Innovation, Education, Consultation and Organization Company, Alter Group, Istanbul, Türkiye.
Abstract:
Sclerostin is a key inhibitor of the Wnt signaling pathway, functioning by binding to the LRP5/6 receptor. This interaction inhibits beta-catenin expression, resulting in the downregulation of osteogenic markers, which contributes to the promotion of osteoporosis and an increase in osteoclast numbers. The primary objective of this research was to investigate the effects of sclerostin antibody (Scl-ab) on bone formation utilizing graft materials in tooth sockets, and to analyze the regulatory interaction between sclerostin and bone tissue through targeted sclerostin inhibition and stimulation of bone formation in tooth extraction sockets following local, single-dose administration. In this study, New Zealand male rabbits (3 months old, weighing 2.5-3 kg) were fully randomized to minimize bias. The experiments were conducted across five groups: a control group, a graft group, and three experimental groups receiving 100%, 75%, and 50% doses of Scl-ab. Calculated doses of Scl-ab were administered alongside the graft material in the extraction sockets, with results assessed at 2 and 4-week intervals. Cone-beam computed tomography indicated that the tooth extraction sockets treated with varying ratios of Scl-ab with graft material exhibited a statistically significant increase in the mean mandibular BV/TV ratio compared to the control and graft groups, with variations based on time and dosage. While bone volume improved over time, the most significant enhancement was observed in the 100% Scl-ab group. Additionally, the administration of different doses of Scl-ab significantly increased trabecular thickness of the alveolar bone compared to both the control (p < 0.001) and graft (p < 0.001) groups, with histological analysis corroborating these findings. The therapeutic application of Scl-ab facilitates early bone formation, and the localized inhibition of sclerostin secreted within the bone microenvironment targets potential bone regeneration.
Insights
Sclerostin antibody (Scl-ab) significantly enhanced bone formation and increased bone volume in rabbit tooth extraction sockets. Localized inhibition of sclerostin promotes early bone regeneration and trabecular thickness.
Area of Science:
- Bone biology and regenerative medicine
- Wnt signaling pathway modulation
- Osteoporosis research
Background:
- Sclerostin inhibits bone formation by blocking Wnt signaling via LRP5/6 receptors.
- Elevated sclerostin levels are linked to osteoporosis and increased osteoclast activity.
- Targeting sclerostin offers a potential strategy for bone regeneration.
Purpose of the Study:
- To evaluate the efficacy of sclerostin antibody (Scl-ab) in promoting bone formation within graft materials in tooth extraction sockets.
- To analyze the effects of localized sclerostin inhibition on bone regeneration and tissue characteristics.
Main Methods:
- New Zealand male rabbits were used, randomized into five groups (control, graft, and three Scl-ab dose groups).
- Scl-ab was administered with graft material into extraction sockets, with assessments at 2 and 4 weeks.
- Cone-beam computed tomography and histological analysis were employed to measure bone parameters.
Main Results:
- Scl-ab treatment significantly increased the mean bone volume/tissue volume (BV/TV) ratio in extraction sockets.
- A dose-dependent increase in bone volume was observed, with the highest dose showing the most significant enhancement.
- Scl-ab administration significantly improved trabecular thickness of the alveolar bone compared to control and graft groups.
Conclusions:
- Localized administration of sclerostin antibody effectively promotes early bone formation in tooth extraction sockets.
- Scl-ab demonstrates therapeutic potential for enhancing bone regeneration by targeting sclerostin in the bone microenvironment.
- This approach holds promise for treating conditions involving bone loss and facilitating socket healing.

